Routine Cryptococcal Screening in Nyanza Province, Kenya
description
Transcript of Routine Cryptococcal Screening in Nyanza Province, Kenya
RoutineCryptococcal Screening in Nyanza Province, Kenya
Jeremy Penner
XIXth International AIDS ConferenceTUSA08, 24 Jul 2012
Outline
• Setting• Screening protocol• Treatment protocol• Intervention uptake• Patient outcomes
Family AIDS Care and Education Services
Screening Protocol• All new enrollments
– Hematology sample for baseline CD4 to central lab– Serum for RPR also part of baseline specimens
• Lab reflex testing, starting Nov 2009– If enrollment CD4 ≤ 100 cells/μl, perform latex agglutination for sCrAg
• If sCrAg + (titre ≥ 1:2)– Results and treatmentprotocol sent to site
Treatment Protocol
“This patient has tested positive for cryptococcal infection…should be treated with…”
• Fluconazole– 1,200mg x 2 weeks– 800mg x 8 weeks– 200mg maintenance
• ART– At 2 weeks if asymptomatic– At 6 weeks if signs/symptoms of meningitis
Uptake: Routine Program Data
Enrolled
CD4 Documented
CD4 ≤ 100
sCrA
g Docu
mented
sCrA
g +
Fluco
nazole
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000Only 68% of new enrollees had CD4 documented in lab database
10,385
15,260
1,865108
1,72679
Uptake: Chart Reviews from 2 Districts
Enrolled
CD4 Documented
CD4 ≤ 100
sCrA
g Docu
mented
sCrA
g +
Fluco
nazole
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000 4,7574,348
806 508
53 47
91% had CD4performed
63% had sCrAgperformed 89% received
fluconazole
Overall Uptake:53%
Outcomes: Methods• Inclusion criteria: Newly enrolling adults with
CD4 count ≤ 100 cells/μl • Intervention group:
– Enrolled between 1 Nov 09 & 31 May 10• Historical control:
– Enrolled between 1 Apr 09 & 31 Oct 09• Primary endpoint: All-cause mortality• Analysis: Cox proportional hazards
– Censored at date of death, last clinic visit, or home visit (for those confirmed alive)
Eligibility and EnrollmentAll new enrollees
12,211
No information18 (0.1%)
Child <15 years 2,680 (22%)
CD4≤1001,595 (17%)
CD4>1007,118 (75%)
CD4 not done399 (4%)
File missing401 (4%)
Adult ≥ 15 years 9,513 (78%)
Charts abstracted1,547 (97%)
Dead 383 (25%)Alive 877 (57%)
Transfer 169 (11%)Unknown 118 (8%)
1,222 person-years follow-up
ResultsControln=771
Interventionn=776
p
Age (years) 34 35 .94
Female 55% 53% .42
Body Mass Index 18.6 18.8 .40
CD4+ T-cell count (cells/μl) 45 41 .35
Started on ART during follow up period
76% 77% .63
Time between enrollment and ART initiation (weeks)
4 4 .08
Received anti-tuberculosis medication
27% 23% .10
Kaplan-Meier Survival Curve Comparing Control to Intervention
HR=1.1, p=.41
HR=1.0 [0.9, 1.3]
Survival Curves Comparing sCrAg + to sCrAg - in Intervention Group
HR=1.06, p=.09
HR=1.6 [1.0, 2.7]
Summary• Limited uptake
– CD4: capacity of central labs; lab networking– sCrAg: stock-outs; lab staff turn-over; workload– Fluconazole: early deaths before starting treatment– Documentation
• Overall survival not improved compared to historical control– Poor uptake– Treatment may not be adequate
• Survival of sCrAg + patients better than expected if no intervention
Acknowledgements• Crypto team:
– Ana-Claire Meyer– Caroline Kendi– Noel Odhiambo– Benard Otieno– Edwin Omondi– Elizabeth Opiyo– Patrick Oyaro– Elizabeth Bukusi– Craig Cohen
• FACES staff and patients, esp the Social Science Department
• Ministries of Health, Government of Kenya
• Institutions:– Kenya Medical Research Institute– University of California San
Francisco– US Centers for Disease Control and
Prevention, Kenya– University of British Columbia
• This work was supported by:– President’s Emergency Plan for
AIDS Relief (U62/CCU924511)– American Academy of Neurology
Foundation Practice Research Training Fellowship
– Fogarty International Clinical Research Fellowship (5 R24 TW00798; 3 R24 TW00798-02S1)
– Hellman Family Foundation